Mylan, Disney to increase visibility of EpiPen access locations

Mylan has signed a multiyear agreement with Walt Disney Parks and Resorts to increase awareness of anaphylaxis, including access to epinephrine auto-injectors, according to a press release.

Updated maps in Disney’s domestic theme parks and on its cruise ships and updated signage in the parks will highlight locations of epinephrine auto-injectors, the release said. The companies also plan on introducing educational resources “designed to increase awareness of preparedness for severe allergic reactions.”

Locations of epinephrine 0.3 mg and 0.15 mg auto-injectors (EpiPen and EpiPen Jr., Mylan) on the Disney cruise ships and theme parks will be available before year’s end, the release said, with guide maps including an EpiPen Auto-Injector symbol and new signage at first aid stations.

“For our guests who live with severe allergies every day, identifying EpiPen locations is an additional tool they’ll have for their anaphylaxis management plan,” Pamela Hymel, MD, MPH, FACOEM, chief medical officer for Walt Disney Parks and Resorts, said in the release.

Heather Bresch

“Like life, severe allergic reactions are unpredictable, so people need to be prepared,” Heather Bresch, Mylan chief executive officer, said in the release. “We are very proud to be working with Disney, which already has a strong reputation for meeting the needs of people managing severe allergies, and we believe we can further raise awareness of anaphylaxis through this collaboration and our joint commitment to education.”